We presented a 39-year-old male who developed progressive cancer disease 4 years after nephrectomy due to clear cell carcinoma.
CASE PRESENTATION
In case of long-term response we should use a next line TKI and in short-term responders we should use an mTOR inhibitor [14, 15] . Metaanalyzes present greater benefit (OS, PFS) from a sequence TKI-mTOR than TKI-TKI. However, these analyzes include limited data from the axitinib treatment [16] . Further prospective studies are needed. Adverse events of everolimus are mucositis (stomatitis, diarrhea), fatigue, pulmonary disorders (non-infectious pneumonitis), metabolic disorders and hematological toxicity.
When choosing the next line treatment for our patient with mRCC, an individual approach seems to be reasonable -according to patients general condition and its comorbidities. It should be the drug, which potentially will not worsen the quality of life of the patient and which the side effects we can cope with [17] . He is the longest treated patient, with a full dose of 10 mg everolimus and without clinical toxicity, among patients treated in our clinic.
